Investigational drug · Phase 2
RVP-001
Also called: Mn-PyC3A, mangaverate
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Central Nervous System (CNS) Lesions, Brain Metastases, Brain Neoplasms.
Phase 2Last checked: Nov 20, 2026Latest source record: Dec 26, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "RVP-001"
First trial start
2024
Aug 15, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RVP-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Central Nervous System (CNS) Lesions
- Brain Metastases
- Brain Neoplasms
- Brain Neoplasms, Benign
- Brain Tumor, Primary
- Brain Tumor, Recurrent
- Brain Tumors
- Brain Cancer
- Brain Tumor
- Brain Neoplasm, Primary
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "RVP-001" as an intervention, largest first.
Reveal Pharmaceuticals Inc.Industry
NCT05413668 · 32 participants · Start May 18, 2022 · Primary completion Jul 22, 2022
Drug: RVP-001; Placebo · For: Healthy
Sites: Miami, Florida
- Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast AgentCompleted
Reveal Pharmaceuticals Inc.Industry
NCT06322342 · 18 participants · Start Aug 15, 2024 · Primary completion Dec 19, 2025
Drug: RVP-001 · For: Central Nervous System (CNS) Lesions; Brain Metastases; Brain Neoplasms and 22 more
Sites: New Haven, Connecticut; Boston, Massachusetts; Columbia, Missouri · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Gadolinium toxicity: mechanisms, clinical manifestations, and nanoparticle role.
Domingo JL, Semelka RC · Arch Toxicol 2025
- Divalent Manganese Complexes as Potential Replacements for Gadolinium-Based Contrast Agents.
Caravan P · Invest Radiol 2024
- A New Era in Magnetic Resonance Contrast Media.
Runge VM, Heverhagen JT · Invest Radiol 2024
- Contrast-Enhanced Cardiac Magnetic Resonance Imaging With a Manganese-Based Alternative to Gadolinium for Tissue Characterization of Acute Myocardial Infarction.
Bonner BP, Yurista SR, Coll-Font J, et al. · J Am Heart Assoc 2023
- Positron Emission Tomography-Magnetic Resonance Imaging Pharmacokinetics, In Vivo Biodistribution, and Whole-Body Elimination of Mn-PyC3A.
Zhou IY, Ramsay IA, Ay I, et al. · Invest Radiol 2021
- Tumor Contrast Enhancement and Whole-Body Elimination of the Manganese-Based Magnetic Resonance Imaging Contrast Agent Mn-PyC3A.
Erstad DJ, Ramsay IA, Jordan VC, et al. · Invest Radiol 2019
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.